Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Iijima, Takashi; Suwabe, Tatsuya; Sumida, Keiichi; Hayami, Noriko; Hiramatsu, Rikako; Hasegawa, Eiko; Yamanouchi, Masayuki; Hoshino, Junichi; Sawa, Naoki; Takaichi, Kenmei; Oohashi, Kenichi; Fujii, Takeshi; Ubara, Yoshifumi
• Is Part Of: Modern rheumatology. Volume 25:Issue 1(2015)
• Page Start: 138
• Page End: 142
• Publication Date: 2015-01
• Subjects: Rheumatology -- Periodicals; 616.723005
• DOI: 10.3109/14397595.2013.874748
• Languages: English
• ISSNs: 1439-7595

Abstract

<abstract> <title>Abstract</title> <p>We report a Japanese woman with systemic rheumatoid vasculitis (SRV) complicated by necrotizing crescentic glomerulonephritis (NCGN). Rheumatoid arthritis first occurred at the age of 19 years, followed by interstitial pneumonia, hepatitis, rheumatoid nodules, mononeuritis multiplex, and hypocomplementemia in chronological order. At the age of 51 years, rapidly progressive renal failure occurred with nephrotic proteinuria, and NCGN with subepithelial deposits was revealed by renal biopsy. Severe destructive changes of multiple joints and scleritis were detected, but anti-neutrophil cytoplasmic antibody was negative on enzyme-linked immunosorbent assays and indirect immunofluorescence. SRV was diagnosed due to involvement of multiple extra-articular organs. An anti-interleukin (IL)-6 receptor antibody (tocilizumab) was started at dosage of 280 mg (8 mg/kg) monthly. After 18 months, her serum creatinine decreased from 1.7 to 1.3 mg/dL, and urinary protein excretion declined from 5.2 to 1.2 g daily. Tocilizumab may be a therapeutic option for SRV associated with NCGN.</p> </abstract>